tbuckley/cabot-search huggingface dataset:
Rituximab is associated with increased risk of Progressive Multifocal Leukoencephalopathy developing among non-HIV-infected Veterans with Chronic Lymphocytic Leukemia.
Authors: LeAnn B. Norris, Peter Georgantopoulos, Gowtham A Rao, A. Oliver Sartor, Charles L. Bennett
Journal: Journal of Clinical Oncology (2015)

e18033 Background: PML is a rare, fatal disease that results from reactivation of the JC virus during immunosuppressed states. Previously we reported that rituximab is associated with a 5-fold increased risk of PML among non-HIV-infected Veterans with non-Hodgkins lymphoma. We now report on risks of PML among rituximab-treated Veterans with CLL. Methods: Electronic medical records from the VA were used to identify non-HIV-infected Veterans with CLL who developed PML (study years: 2003 to 2011). Results: 6/26,597 Veterans with CLL developed PML (0.023%). 4/2,425 non-HIV-infected Veterans with CLL who received rituximab developed PML (16.5 per 10,000). Non-HIV-infected Veterans who did't receive rituximab, 2/24,172 developed PML (0.8 per 10,000). This results in a statistically significant unadjusted relative risk of 19.9 (95% CI: 3.6 – 108.8) and an attributable risk of 15.7 per 10,000 non-HIV-infected Veterans with CLL. Univariate analyses of other outcomes were not statistically significant between patients who received and those who did not receive rituximab (Table). Conclusions: Among non-HIV-infected Veterans with CLL, rituximab use is associated with a 19.9-fold increased risk for subsequent development of PML (p<0.05). Serial measurement of JC virus titers during long-term rituximab therapy among non-HIV-infected Veterans with CLL should be considered (as is currently done with multiple sclerosis patients who receive long-term natalizumab). PML Veterans with CLL who received rituximab (n=4) PML Patients with CLL who didn't receive rituximab (n=2) Male (%) 4 (100) 2 (100) Died (%) 3 (75.0) 2 (100) Median age in years at death (range) 68.6 years (53.2 – 72.8) 79.1 years (78.5 – 79.6) Median age at PML diagnosis (range) 69.5 years (53.0 – 72.8) 79.0 years (78.4 – 79.5) Median time to death from lymphoma diagnosis (range) 83.9 mo (31.2 – 109.9) 15.1 mo (11.5 – 18.7) Median time to death from PML diagnosis (range) 0.9 mo (0.2 – 2.1) 1.0 (0.9 – 1.0) Median time to PML diagnosis from lymphoma diagnosis (range) 80.9 mo (29.1 – 109.6) 14.1 mo (10.5 – 17.8) Median time to PML diagnosis from first rituximab dose (range) 40.7 mo (16.4 – 108.6) N/A
Patient presentation, quality of care, and overall survival in colorectal cancer: Results from the New Zealand PIPER Cohort Study.
Authors: Christopher G. C. A. Jackson, Katrina J. Sharples, Melissa J. Murray, Victoria A. Hinder, Dale M. Bramley, Charis Brown, Sarah Derrett, Andrew G. Hill, Mark Jeffery, John P. Keating, Ross A. Lawrenson, Papaarangi Reid, Diana Sarfati, Adrian Secker, Michael P. N. Findlay
Journal: Journal of Clinical Oncology (2015)

e17637 Background: New Zealand (NZ) has amongst the highest rates of colon and rectal cancer in the world. NZ has no national screening program and access to systemic cancer therapies is tightly controlled. We conducted a retrospective national cohort study (The PIPER Project) of all patients diagnosed with colorectal cancer in NZ between 2007 and 2008. Methods: A retrospective clinical note review was undertaken from all health records for patients diagnosed with adenocarcinoma of the colon or rectum during the calendar years 2007 and 2008. These were linked to national morbidity and mortality databases using a unique patient identifier (the National Health Index, NHI). Results: 5667 patients were identified. Location of primary tumor and stage were consistent with an unscreened population. 31% of patients presented as an emergency, and 19% of all patients presented with bowel obstruction. The 5-year survival was 36.0% (95% CI 33.7-38.4%) for those presenting as an emergency, compared with 56.1% (95% CI 54.4-57.7%) for non-emergency (p < 0.0005). For those presenting with obstruction, the 5-year survival was 35.6% (95% CI 32.6-38.6%) and without obstruction it was 50.4% (95% CI 48.9-52.0%), p = < 0.0005. Differences remained highly significant after adjusting for age, sex, stage and comorbidity. The 5-year overall survival rate for the entire cohort was 51.6% (95% CI = 50.2-52.9%), considerably lower than the SEER reported rate of 65.9%. We report on key indicators that contribute to this high mortality rate including patterns of presentation, ethnicity, distance to treatment center, and the impact of utilization of adjuvant and systemic therapies. Conclusions: This study underlines the importance of detection of colorectal cancer prior to emergency or obstructed presentation, and describes the impact of systemic therapies on survival in a national study.
Publisher Correction: Large-area MRI-compatible epidermal electronic interfaces for prosthetic control and cognitive monitoring
Authors: Limei Tian, Benjamin Zimmerman, Aadeel Akhtar, Ki Jun Yu, Matthew Moore, Jian Wu, Ryan J. Larsen, Jung Woo Lee, Jinghua Li, Yuhao Liu, Brian Metzger, Subing Qu, Xiaogang Guo, Kyle E. Mathewson, Jonathan A. Fan, Jesse Cornman, Michael Fatina, Zhaoqian Xie, Yinji Ma, Jue Zhang, Yihui Zhang, Florin Dolcos, Monica Fabiani, Gabriele Gratton, Timothy Bretl, Levi J. Hargrove, Paul V. Braun, Yonggang Huang, John A. Rogers
Journal: Nature Biomedical Engineering (2019)
Inpatient care directed by hospitalists vs. oncologists: Comparison of patient satisfaction and outcomes.
Authors: Peter John Oppelt, Pingfu Fu, Jonathan Wynbrandt, Shelly Fiala, Paula Silverman
Journal: Journal of Clinical Oncology (2015)

e17645 Background: Inpatient oncology hospitalists represent a growing entity. There is limited data describing the quality of care for inpatients cared for by an oncology hospitalist compared to an oncologist. At our institution, oncology inpatients are distributed onto teaching services supervised by either a hospitalist or an oncologist. Methods: Charts for patients discharged from oncology services between April 1-June 30, 2014 were reviewed. Data collected included length of stay (LOS), readmission rates, cost, reimbursement, consult service utilization, and disposition. Patient satisfaction scores from Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) were also obtained. Results: A total of 311 charts were reviewed (163 hospitalist, 148 oncologist). There was no difference between LOS or readmission rates for patients cared for by hospitalists compared to oncologists (LOS 5.2 days vs 5.4 days p=0.337; readmission rates 38% vs 32% p=0.246). Costs ($12,555 vs $13,911 p= 0.327) and reimbursement ($14,709 vs $15,182 p=0.795) were also similar for each group. Consulting services utilized per hospitalization were also similar for hospitalists compared to oncologists (1.23 vs 1.32 p=0.464). Responses to 146 HCAHPS surveys were available with no difference in satisfaction with their doctors or overall assessment of the hospital (Table). Conclusions: Oncology hospitalists and medical oncologists provide equally good inpatient care. As the number of oncology patients cared for by hospitalists continues to rise, this data provides reassurance that quality and patient satisfaction will remain at the same level as that for those cared for by oncologists. Hospitalist Oncologist HCAHPS Question n Mean n Mean p value Rate hospital (0 – 10) 97 8.5 47 8.55 0.79 Recommend hospital (1 – 4) 98 3.79 46 3.78 0.97 Doctors treat with courtesy/respect (1-4) 97 3.8 46 3.8 0.97 Doctors listen to you (1-4) 98 3.76 47 3.79 0.72 Doctors explain in a way you understand (1-4) 99 3.64 46 3.65 0.88
Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience
Authors: Kalyan Nadiminti, Christopher Strouse, Praveen Vikas, Lindsay Dozeman, Allyson Schultz, Sarah L Mott, Jillna Claus, Umar Farooq, Margarida Silverman, Michael Tomasson, Fenghuang Zhan, Yogesh Jethava, Guido J. Tricot
Journal: Blood (2018)
Survival analysis of patients with breast cancer in a outpatient cancer center in Rio de Janeiro, Brazil.
Authors: Aline Coelho Goncalves, Alexandre Boukai, Nelson Teich, Daniela Guimaraes da Silava, Karina Duarte Silva, Perla de Mello Andrade, Thamirez de Almeida Vieira, Thamires Castro Almeida, Cleise Silva, Debora Victorino de Azevedo, Monica Schaum
Journal: Journal of Clinical Oncology (2015)

e12629 Background: Globally, breast cancer is the most frequently diagnosed type of cancer and the leading cause of cancer death in women. In the United States (US), it is the second most common cause of cancer death among women. According to data from the National Cancer Institute (NCI), in 2014 were estimated 232,670 new cases in the US and 40,000 deaths. The 5-year relative survival in the US is 89%.(1) In Brazil, according to the Brazilian National Cancer Institute (INCA) , breast cancer is the most common type of cancer among women. In 2014, 57.120 new cases were estimated. In 2011, the number of deaths from breast cancer was 13.345 women. Several factors are related to high breast cancer mortality in Brazil, including: late diagnosis, delayed start of treatment, demographic and socioeconomic characteristics of the population. The aim of this present report is to evaluate the overall survival of Brazilian patients with breast cancer diagnosis treated in a outpatient cancer center in Rio de Janeiro, Brazil. Methods: We reviewed data from 487 patients with breast cancer who were admitted in our cancer center during the period from 01/01/2009 to 12/31/2011. The overall survival was calculated as the range from the date of diagnosis until the date of death. The survival curve was estimated by the Kaplan- Meier method, using the log-rank test fot comparison of the curves. Results: 487 patients were included in this present report during the period ranging from 01/01/2009 to 07/31/2014. 35 events were observed, all deaths related to breast cancer. The patients staging I, II, III, IV were respectively 41%, 38%, 17% and 4%. The overall survival rate according to stages I, II, III and IV were respectively 95,7 %, 94% , 80,4% and 56,3%. The 5-years overall survival rate for all patients treated at our institution during this period was 90,9%. Conclusions: The overall survival rate of this population is higher than the expected overall survival rate in Brazil and is similar to overall survival rate reported in the US. The diagnosis in advanced stage is one of the most important factors for worse survival in our country.
Findings from a combined prospective and retrospective risk analysis of chemotherapy: From prescription to administration.
Authors: Elisabeth Ruijgrok, Arjen Procé, Maya Ramrattan
Journal: Journal of Clinical Oncology (2015)

e17665 Background: The process of chemotherapy prescription, preparation and administration represents a number of threats to patient safety. Identification of these risks is critical for improving patient safety. This study describes a combined retrospective and prospective risk analysis of the chemotherapy process in a large teaching hospital. Methods: The prospective risk analysis was carried out by determining potential failures for each step of the chemotherapy process (prescribing, preparation, transportation, administration). To determine the risk of every potential failure, a decision algorithm was used by a multidisciplinary team. Preventive measures were proposed to control or eliminate the identified risks. The retrospective risk-analysis consisted of the analysis of the incidents reported in the hospital reporting system. Results: 17 Potential high-risk failures were found in the prospective risk analysis, mainly in the prescription and preparation process. 14 Unique preventive measures were proposed and implemented. In the retrospective risk analysis, all hospital incident reports (January 2012 – June 2014) were assessed. The chemotherapy process accounted for 119 (10%) of all medication related incidence reports. Most of these incidents took place during preparation in the pharmacy. There was a high level of discrepancy between the expected (frequency of) risk failures in the prospective risk analysis and the recorded incidents. Although mitigation of risks through checks by hospital staff was expected in the prospective risk-analysis, the analysis of incident reports showed that human error is an important denominator. Conclusions: Risk analysis of critical processes in cancer care can help to improve patient safety. This study shows that prospective analysis and retrospective incident reporting both reveal unique risks. Both methods should therefore be combined, in order to select the right interventions for preventing errors.
Return of sleep apnoea and sleep fragmentation following CPAP withdrawal in patients with obstructive sleep apnoea
Authors: Chris Turnbull, Saxon Pattenden, Thomas Gaisl, Valentina Rossi, Sira Thiel, Malcolm Kohler, John Stradling
Journal: European Respiratory Journal (2019)

<b>Following CPAP withdrawal, in some obstructive sleep apnoea patients, evidence of sleep fragmentation can occur prior to the appearance of significant oxygen desaturations</b>http://ow.ly/OhoN30o957o
Abstract 16114: Risk Identification of Drug-induced Long QT Syndrome Using a Patient-specific Long QT-JT Risk Score
Authors: Lauren E Steffen, Calvin H Knowlton, Jacques Turgeon
Journal: Circulation (2016)

Our research is focused on the drug-induced Long QT Syndrome (LQTS) and its relationship to the potentially fatal polymorphic ventricular tachycardia, Torsade de Pointes (TdP). It was our objective...
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).
Authors: David Malka, Florence Castan, Eric Francois, Olivier Bouche, Jaafar Bennouna, Francois Ghiringhelli, Christelle De La Fouchardiere, Christophe Borg, Emmanuelle Samalin, Jean Baptiste Bachet, Jean-Luc Raoul, Frédérique Cvitkovic, Laurent Miglianico, Leila Bengrine-Lefevre, Laetitia Dahan, Cedric Lecaille, Thomas Aparicio, Herve Perrier, Sophie Gourgou, Julien Taïeb
Journal: Journal of Clinical Oncology (2015)

4013 Background: EGFR and HGF/c-Met pathways are often deregulated in AGEA. We assessed whether EGFR or HGF inhibition with panitumumab or rilotumumab is beneficial in the first-line treatment of pts with AGEA. Methods: Pts ≥18 yrs with non-HER2+, measurable AGEA and ECOG performance status (PS) 0-1 were randomized (minimization procedure; stratification factors: Lauren classification, disease stage, center) to mFOLFOX6 (oxaliplatin 85 mg/m², folinic acid 400 mg/m², fluorouracil: 400 mg/m² bolus then 2400 mg/m² over 46 h) alone (arm A) or combined to panitumumab (6 mg/kg; arm B) or rilotumumab (10 mg/kg; arm C), every 2 weeks until limiting toxicity or disease progression. The primary endpoint was 4-month progression-free survival rate (4-PFS) (Fleming’s one-step design, one-sided Α=5%, Β=10%, H0: 40%; H1: 60%; 153 evaluable pts needed). Results: 162 pts (median age, 64 [range, 23-87]; ECOG PS 0/1, 33/67%) were enrolled from 2011/01/14 to 2013/08/19 in 29 French centers. Most had metastatic (97%), intestinal (69%) adenocarcinoma of the stomach (50%) or GE junction (30%). Main results were (median follow-up, 23.6 months; 95%CI, 19.7-27.3): Conclusions: All combination regimens reached the primary study endpoint. Adding panitumumab or rilotumumab seemed more toxic and not more effective than mFOLFOX6 alone. Subgroup analyses according to tumor biomarker status (e.g., RAS/BRAF and MET) will be presented later. Clinical trial information: 2009-012797-12. mFOLFOX6 (n=56) mFOLFOX6 + panitumumab (n=49) mFOLFOX6 + rilotumumab (n=57) Median number of cycles 10.5 9 11 G3+ adverse events 1,2 62 83 90 Peripheral neuropathy (%) 17 6 33 Neutropenia (febrile) (%) 26 (0) 27 (8) 28 (5) Asthenia (%) 6 17 14 Diarrhea (%) 4 15 2 Anemia (%) 4 10 5 Vomiting (%) 4 10 4 Rash (%) 2 10 2 Objective response rate (%) [95%CI] 3 54 [40-67] 44 [30-59] 50 [36-64] 4-PFS (%) 3 71 [57-82] 63 [48-77] 63 [49-75] Median PFS (months) [95%CI] 3 5.8 [5.2-7.3] 5.2 [3.7-7.6] 7.6 [4.0-9.0] Median overall survival (months) [95%CI] 13.1 [8.7-16.9] 8.3 [6.2-16.9] 11.5 [7.9-17.1] 1n = 159 pts evaluable for safety. 2 G5, 1/4/3 pts, respectively. 3n = 158 evaluable pts (intent-to-treat population).
Molecular Characterization of Acute Myeloid Leukemia (AML) Patients Who Relapse More Than 3 Years after Diagnosis: An Exome Sequencing Study of 31 Patients
Authors: Luise Hartmann, Niroshan Nadarajah, Manja Meggendorfer, Anna Stengel, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2018)
Rural oncology mission in central Indian state: Report from a unique cancer program.
Authors: Dinesh Pendharkar, Adnan Ali, C M Tripathi, Manoj Pandey, B K Gautam
Journal: Journal of Clinical Oncology (2015)

e17526 Background: Currently cancer patients in rural areas have to overcome a wide array of geographic, economic and cultural barriers to receive treatment at cancer centers in urban conglomerations resulting in “lost to follow ups” and treatment interruptions. Therefore, cancer patients in rural India have an ardent desire to receive organized, affordable and state-of-the-art cancer treatment close to their abode. To overcome these hurdles a state wide rural oncology program, was designed and implemented in the Indian state of Madhya Pradesh( Partners-Govt of Madhya Pradesh ,Asian Institute of Oncology and Medical Education Trust-NGO). Methods: The project was initiated in February 2014 by establishment of chemotherapy units in all 51 district hospitals of MP state government. To do so, one physician and two nurses selected from each district hospital underwent mandatory training at tertiary cancer hospitals under a medical oncologist. Implementation of data registry was initiated .A visiting consulting medical oncologist periodically visited and supervised physicians and allied health staff on enrollment, management, counseling and chemotherapy administration. Results: A total of 49 physicians and 101 staff nurses were trained at three tertiary level cancer centers. Between February 2014 and January 2015, 4933 cancer patients were registered, of which 419 (8.5%) were administered chemotherapy and managed in district hospitals of MP. On subset analysis of data from 5 districts (659 patients) showed that 330 (50.1%) were males [median age (Interquartile range): 55 years (45, 62)] and 329 (49.9%) females [median age (Interquartile range) 50 years (40, 60)]. The three most common cancers were found to be breast (n = 136, 41.3%), cervix (n = 29, 8.8%) and ovary (n = 28, 8.5%) among females and tongue (n = 42, 12.7%), lung (n = 37, 11.2%) and buccal mucosa (n = 35, 10.6%) among males. Conclusions: Through the rural community oncology empowerment setups, we have established a state wide supervised network of rural chemotherapy units. In contrast to national data breast cancer appears to be leading cancer in women and tongue to be commonest site among oral cancers. This model could serve as a unique opportunity for service and research.
Abstract P049: Circulating Adiponectin Levels and Risk of Type 2 Diabetes, Cardiovascular Disease, and All-Cause Mortality in US Women
Authors: Jie Hu, Jun Li, Liming Liang, Tianyi Huang, Frank B Hu, JoAnn E Manson, Shelley S Tworoger, Kathryn M Rexrode
Journal: Circulation (2019)

Introduction: Adiponectin is an anti-inflammatory peptide hormone secreted by adipocytes and has been related with decreased risk of type 2 diabetes (T2D) and cardiovascular disease (CVD), but longitudinal data are limited and inconsistent. Hypothesis: Higher circulating adiponectin levels are associated with lower risk of T2D, CVD, and all-cause mortality in healthy women. Methods: Baseline adiponectin levels, measured by an immunoassay, were available on 15,131 women from the Nurses’ Health study I and II, who were part of 11 separate nested case-control studies and free of T2D, CVD, and cancer at study baseline. Associations of adiponectin levels with incident T2D, CVD (including coronary heart disease [CHD], stroke, and CVD death), and all-cause mortality were estimated using Cox regressions adjusted for study design characters, established risk factors and confounders including menopausal status, hormone therapy, and continuous body mass index. We also analyzed associations of 26 adiponectin expression-associated variants (in adipose tissue) with T2D, CVD, and all-cause mortality in the UK Biobank study. Results: During up to 22 years (289,408 person-years) of follow-up, 2,578 T2D cases, 1,827 CVD cases (including 745 CHD, 1,108 stroke and 428 CVD deaths), and 2,741 deaths occurred. In multivariable models, hazard ratios (95% confidence intervals) comparing the highest quartile of plasma adiponectin to the lowest were 0.17 (0.14-0.21; P trend &lt;0.001) for T2D, 0.82 (0.69-0.96; P trend =0.005) for CVD, 0.66 (0.51-0.86; P trend &lt;0.001) for CHD, 0.91 (0.73-1.12; P trend =0.34) for stroke, 0.69 (0.48-0.98; P trend =0.10) for CVD death, and 0.77 (0.66-0.90; P trend =0.005) for all-cause mortality. Genetic alleles associated with increased adiponectin expression in adipose tissue were associated with decreased risk of CVD, but no associations were observed for T2D and all-cause mortality. Conclusions: Higher adiponectin levels are associated with decreased risk of cardiometabolic diseases and all-cause mortality.
Association between chronic hepatitis C, HIV, and hepatitis C/HIV co-infection and the development of colorectal adenomas.
Authors: Jorge Miguel Hurtado, Lipka Seth, Ashley Davis-Yadley, Magdalene Vardaros, Huafeng Shen, R. Judith Ratzan
Journal: Journal of Clinical Oncology (2015)

e12585 Background: Limited knowledge exists about the effects chronic hepatitis C virus (HCV) infection has in the development of colorectal adenomas (CRA). Data regarding the association between chronic HIV infection and the development of CRA is scarce as well. We aim to determine if there is an association between the development of CRA and chronic infection with HCV, HIV, and HCV/HIV coinfection. Methods: From July 1, 2009 to March 31, 2011 a total of 2,051 patients that underwent colonoscopy were included in our study. The population was divided into 3 study groups: those patients who tested positive for HCV, HIV, and HCV/HIC; the control groups consisted of patients whose results were negative. Fisher’s exact χ2 test for categorical variables and t-test for continuous variables was used to analyze data between groups. Logistic regression was performed to obtain odds ratios. Results: CRA detection was higher in the HCV than in the control group (26.3% vs. 20.2% P=0.93); Likewise, the incidence of CRA (25.5% vs. 20.8; P = 0.63) was higher in the coinfection group. However, our data failed to reach statistical significance. No difference in CRA detection was found between the HIV and non-HIV patients (20.4% vs. 22% P=0.73). Conclusions: This study shows a positive correlation between HCV and HIV/HCV co-infection and the incidence of CRA; whether co-infection with these two viruses has a synergistic effect remains to be determined. Our results demonstrated that patients with HCV and HIV/HCV will benefit from screening colonoscopy at an earlier age. Once these patients develop colorectal cancer, treatment is hindered by their comorbidities, and interactions between chemotherapeutic and anti-viral drugs. Validation of our results in a large multi-center prospective study could lead to the implementation of guidelines that will favor earlier screening colonoscopy in these patients. No Hepatitis C (n= 1,008) Hepatitis C (n=175) P-value OR (95% CI) Adenoma 204(20.2%) 46(26.3) 0.93 1.02 (0.66, 1.57) Non-HIV/HCV(n= 322) HIV/HCV(n=47) P-value OR (95% CI) Adenoma 67(20.8%) 12(25.5%) 0.63 0.81 (0.34, 1.93) Non-HIV(n= 386) HIV (n=113) P-value OR (95% CI) Adenoma 85(22.0%) 23(20.4%) 0.73 0.90 (0.48, 1.67)